GlassScriptPhysician profile
Richard A Bender
NPI 1255412664
$3,947.75
in general payments reported to CMS, 2019-2025
55 companies · $698 in 2025
The $698 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $298 · 2020: $466 · 2021: $1,028 · 2022: $626 · 2023: $558 · 2024: $274 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,530.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,529.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $238.53 | 2019-2025 | Monjuvi, Jakafi |
| Astrazeneca Pharmaceuticals LP | $235.16 | 2020-2025 | Calquence, Tagrisso, Lynparza |
| Janssen Biotech, INC. | $227.55 | 2020-2025 | Rybrevant |
| Novartis Pharmaceuticals Corporation | $217.46 | 2019-2025 | |
| Glaxosmithkline, LLC. | $210.27 | 2021-2025 | Ojjaara |
| Amgen INC. | $207.14 | 2019-2022 | |
| Pfizer INC. | $183.97 | 2019-2023 | |
| Eisai INC. | $158.16 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $150.89 | 2020-2023 | Lynparza, Welireg, Keytruda |
| Celgene Corporation | $126.18 | 2019-2023 | Pomalyst |
| Seagen INC. | $116.25 | 2019-2023 | Tivdak |
| Sobi, INC | $111.85 | 2022-2025 | |
| Genentech USA, INC. | $103.05 | 2019-2025 | Itovebi, Phesgo |
| Pharmacyclics LLC, An Abbvie Company | $100.12 | 2021-2023 | Imbruvica |
| Gilead Sciences, INC. | $86.58 | 2019-2023 | Trodelvy |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Bender listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.